FDA Inspection 1304468 — Kamlesh Kumar Sankhala, M.D.
The FDA completed an inspection of Kamlesh Kumar Sankhala, M.D. on Feb 17, 2026 in Beverly Hills, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 17, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beverly Hills, CA (United States)
Additional details
Clinical Investigator (CI)